<p>根據 MarketBeat 的報道，覆蓋 Theravance Biopharma, Inc.（NASDAQ:TBPH - 獲取免費報告）的八位分析師給出了 “適度買入” 的共識推薦。三位分析師對該股票給予了持有評級，三位給予了買入評級，另外兩位則給予了強烈買入評級。在過去一年中，發佈報告的分析師對該股票的平均 12 個月目標價格為 21.3333 美元。</p>
<p>獲取 <strong>Theravance Biopharma</strong> 的提醒：</p>
<p>最近，一些分析師對 TBPH 股票發佈了報告。BTIG Research 在 3 月 20 日的報告中重申了 “買入” 評級，並對 Theravance Biopharma 的股票設定了 21.00 美元的目標價。HC Wainwright 在 3 月 2 日的報告中將 Theravance Biopharma 的目標價從 20.00 美元上調至 27.00 美元，並給予該股票 “買入” 評級。Wall Street Zen 在週日的研究報告中將 Theravance Biopharma 的股票評級從 “持有” 上調至 “強烈買入”。Oppenheimer 在 3 月 5 日的研究報告中將 Theravance Biopharma 的股票評級從 “跑贏大盤” 下調至 “市場表現”。最後，B. Riley Financial 在 3 月 4 日的研究報告中重新發布了 “中性” 評級，並將 Theravance Biopharma 的目標價設定為 14.00 美元（從 28.00 美元下調）。</p>
<p><strong>查看我們最新的 TBPH 股票分析</strong></p>
<h2>Theravance Biopharma 股票表現</h2>
<p>NASDAQ TBPH 在週二開盤價為 15.26 美元。Theravance Biopharma 的 52 周低點為 7.90 美元，52 周高點為 21.03 美元。該股票的 50 日移動平均價格為 17.40 美元，200 日移動平均價格為 16.94 美元。該股票的市值為 7.8574 億美元，市盈率為 7.52，貝塔值為 0.17。</p>
<h2>內部活動</h2>
<p>在相關消息中，SVP Rhonda Farnum 在 3 月 16 日的交易中出售了 31,067 股公司的股票。該股票以平均價格 13.96 美元出售，總交易額為 433,695.32 美元。出售後，該高級副總裁持有 232,699 股公司股票，價值約為 3,248,478.04 美元。這代表了他們持有股票的比例下降了 11.78%。該交易已在 SEC 的法律文件中披露，可以通過此超鏈接訪問。公司內部人士持有公司股票的 6.90%。</p>
<h2>機構資金流入和流出</h2>
<p>機構投資者最近對該股票的持倉進行了調整。Vanguard Group Inc.在第三季度將其在 Theravance Biopharma 的股份增加了 2.5%。Vanguard Group Inc.目前擁有 2,211,582 股該生物製藥公司的股票，價值 32,289,000 美元，此前在上個季度購買了 54,152 股。State Street Corp 在第四季度將其在 Theravance Biopharma 的股份增加了 4.4%。State Street Corp 目前擁有 1,101,892 股該生物製藥公司的股票，價值 20,616,000 美元，此前在上個季度購買了 45,987 股。Geode Capital Management LLC 在第四季度將其在 Theravance Biopharma 的持股增加了 4.5%。Geode Capital Management LLC 目前擁有 938,724 股該生物製藥公司的股票，價值 17,567,000 美元，此前在上個季度購買了 40,734 股。Dimensional Fund Advisors LP 在第四季度將其在 Theravance Biopharma 的持股增加了 12.0%。Dimensional Fund Advisors LP 目前擁有 858,957 股該生物製藥公司的股票，價值 16,072,000 美元，此前在上個季度購買了 92,253 股。最後，Arrowstreet Capital Limited Partnership 在第三季度購買了 Theravance Biopharma 的新股份，價值 10,611,000 美元。機構投資者和對沖基金持有公司 99.10% 的股票。</p>
<h2>Theravance Biopharma 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Theravance Biopharma 是一家生物製藥公司，專注於創新藥物的發現、開發和商業化，主要涉及呼吸系統疾病、炎症和免疫學以及罕見疾病領域。該公司開發的小分子療法旨在通過靶向特定的分子通路來滿足未滿足的醫療需求。其主要市場產品 YUPELRI®（revefenacin）吸入溶液是美國批准的首個也是唯一一個每日一次的長效抗膽鹼藥物（LAMA）。</p>
<h2>推薦故事</h2>
<ul>
<li>我們更看好的五隻股票超過 Theravance Biopharma</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEJQSA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEJQSA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Theravance Biopharma 嗎？</h2>
<p>在你考慮 Theravance Biopharma 之前，你會想聽聽這個。</p>
<p>MarketBeat 跟蹤華爾街頂級評級和表現最佳的研究分析師及其每天推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 Theravance Biopharma 並不在名單上。</p>
<p>雖然 Theravance Biopharma 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

Theravance生物制藥

<p>Theravance Biopharma, Inc.（納斯達克代碼：TBPH）獲得了八位分析師的 “適度買入” 共識推薦。平均目標價為 21.33 美元，其中三位分析師給予持有評級，三位給予買入評級，二位給予強烈買入評級。最近的報告顯示，BTIG Research 維持買入評級，目標價為 21.00 美元，而 HC Wainwright 將其目標價從 20.00 美元上調至 27.00 美元。該股票開盤價為 15.26 美元，52 周區間為 7.90 美元至 21.03 美元。機構投資者持有該公司 99.10% 的股份</p>

<p>Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) have been given a consensus recommendation of &#34;Moderate Buy&#34; by the eight analysts that are covering the company, MarketBeat reports. Three analysts have rated the stock with a hold rating, three have assigned a buy rating and two have issued a strong buy rating on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $21.3333.</p>
<div class="lb-trans"><p>根據 MarketBeat 的報道，覆蓋 Theravance Biopharma, Inc.（NASDAQ:TBPH - 獲取免費報告）的八位分析師給出了 “適度買入” 的共識推薦。三位分析師對該股票給予了持有評級，三位給予了買入評級，另外兩位則給予了強烈買入評級。在過去一年中，發佈報告的分析師對該股票的平均 12 個月目標價格為 21.3333 美元。</p>
</div><p>Get <strong>Theravance Biopharma</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Theravance Biopharma</strong> 的提醒：</p>
</div><p>A number of analysts have recently issued reports on TBPH shares. BTIG Research reiterated a &#34;buy&#34; rating and issued a $21.00 price objective on shares of Theravance Biopharma in a report on Friday, March 20th. HC Wainwright increased their target price on shares of Theravance Biopharma from $20.00 to $27.00 and gave the stock a &#34;buy&#34; rating in a report on Monday, March 2nd. Wall Street Zen raised shares of Theravance Biopharma from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research report on Sunday. Oppenheimer lowered shares of Theravance Biopharma from an &#34;outperform&#34; rating to a &#34;market perform&#34; rating in a research note on Thursday, March 5th. Finally, B. Riley Financial reissued a &#34;neutral&#34; rating and set a $14.00 price target (down from $28.00) on shares of Theravance Biopharma in a research report on Wednesday, March 4th.</p>
<div class="lb-trans"><p>最近，一些分析師對 TBPH 股票發佈了報告。BTIG Research 在 3 月 20 日的報告中重申了 “買入” 評級，並對 Theravance Biopharma 的股票設定了 21.00 美元的目標價。HC Wainwright 在 3 月 2 日的報告中將 Theravance Biopharma 的目標價從 20.00 美元上調至 27.00 美元，並給予該股票 “買入” 評級。Wall Street Zen 在週日的研究報告中將 Theravance Biopharma 的股票評級從 “持有” 上調至 “強烈買入”。Oppenheimer 在 3 月 5 日的研究報告中將 Theravance Biopharma 的股票評級從 “跑贏大盤” 下調至 “市場表現”。最後，B. Riley Financial 在 3 月 4 日的研究報告中重新發布了 “中性” 評級，並將 Theravance Biopharma 的目標價設定為 14.00 美元（從 28.00 美元下調）。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on TBPH</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 TBPH 股票分析</strong></p>
</div><h2>Theravance Biopharma Stock Performance</h2>
<div class="lb-trans"><h2>Theravance Biopharma 股票表現</h2>
</div><p>NASDAQ TBPH opened at $15.26 on Tuesday. Theravance Biopharma has a 52 week low of $7.90 and a 52 week high of $21.03. The stock's 50 day moving average price is $17.40 and its two-hundred day moving average price is $16.94. The stock has a market capitalization of $785.74 million, a price-to-earnings ratio of 7.52 and a beta of 0.17.</p>
<div class="lb-trans"><p>NASDAQ TBPH 在週二開盤價為 15.26 美元。Theravance Biopharma 的 52 周低點為 7.90 美元，52 周高點為 21.03 美元。該股票的 50 日移動平均價格為 17.40 美元，200 日移動平均價格為 16.94 美元。該股票的市值為 7.8574 億美元，市盈率為 7.52，貝塔值為 0.17。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>內部活動</h2>
</div><p>In related news, SVP Rhonda Farnum sold 31,067 shares of the company's stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $13.96, for a total transaction of $433,695.32. Following the sale, the senior vice president owned 232,699 shares in the company, valued at approximately $3,248,478.04. This represents a 11.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 6.90% of the company's stock.</p>
<div class="lb-trans"><p>在相關消息中，SVP Rhonda Farnum 在 3 月 16 日的交易中出售了 31,067 股公司的股票。該股票以平均價格 13.96 美元出售，總交易額為 433,695.32 美元。出售後，該高級副總裁持有 232,699 股公司股票，價值約為 3,248,478.04 美元。這代表了他們持有股票的比例下降了 11.78%。該交易已在 SEC 的法律文件中披露，可以通過此超鏈接訪問。公司內部人士持有公司股票的 6.90%。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>Institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its stake in shares of Theravance Biopharma by 2.5% during the 3rd quarter. Vanguard Group Inc. now owns 2,211,582 shares of the biopharmaceutical company's stock worth $32,289,000 after purchasing an additional 54,152 shares in the last quarter. State Street Corp grew its stake in shares of Theravance Biopharma by 4.4% in the fourth quarter. State Street Corp now owns 1,101,892 shares of the biopharmaceutical company's stock valued at $20,616,000 after buying an additional 45,987 shares in the last quarter. Geode Capital Management LLC increased its holdings in Theravance Biopharma by 4.5% during the fourth quarter. Geode Capital Management LLC now owns 938,724 shares of the biopharmaceutical company's stock worth $17,567,000 after buying an additional 40,734 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in Theravance Biopharma by 12.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 858,957 shares of the biopharmaceutical company's stock worth $16,072,000 after buying an additional 92,253 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership bought a new stake in Theravance Biopharma during the third quarter worth $10,611,000. Institutional investors and hedge funds own 99.10% of the company's stock.</p>
<div class="lb-trans"><p>機構投資者最近對該股票的持倉進行了調整。Vanguard Group Inc.在第三季度將其在 Theravance Biopharma 的股份增加了 2.5%。Vanguard Group Inc.目前擁有 2,211,582 股該生物製藥公司的股票，價值 32,289,000 美元，此前在上個季度購買了 54,152 股。State Street Corp 在第四季度將其在 Theravance Biopharma 的股份增加了 4.4%。State Street Corp 目前擁有 1,101,892 股該生物製藥公司的股票，價值 20,616,000 美元，此前在上個季度購買了 45,987 股。Geode Capital Management LLC 在第四季度將其在 Theravance Biopharma 的持股增加了 4.5%。Geode Capital Management LLC 目前擁有 938,724 股該生物製藥公司的股票，價值 17,567,000 美元，此前在上個季度購買了 40,734 股。Dimensional Fund Advisors LP 在第四季度將其在 Theravance Biopharma 的持股增加了 12.0%。Dimensional Fund Advisors LP 目前擁有 858,957 股該生物製藥公司的股票，價值 16,072,000 美元，此前在上個季度購買了 92,253 股。最後，Arrowstreet Capital Limited Partnership 在第三季度購買了 Theravance Biopharma 的新股份，價值 10,611,000 美元。機構投資者和對沖基金持有公司 99.10% 的股票。</p>
</div><h2>Theravance Biopharma Company Profile</h2>
<div class="lb-trans"><h2>Theravance Biopharma 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.</p>
<div class="lb-trans"><p>Theravance Biopharma 是一家生物製藥公司，專注於創新藥物的發現、開發和商業化，主要涉及呼吸系統疾病、炎症和免疫學以及罕見疾病領域。該公司開發的小分子療法旨在通過靶向特定的分子通路來滿足未滿足的醫療需求。其主要市場產品 YUPELRI®（revefenacin）吸入溶液是美國批准的首個也是唯一一個每日一次的長效抗膽鹼藥物（LAMA）。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than Theravance Biopharma</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票超過 Theravance Biopharma</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEJQSA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=TBPH"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Theravance Biopharma Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Theravance Biopharma 嗎？</h2>
</div><p>Before you consider Theravance Biopharma, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Theravance Biopharma 之前，你會想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Theravance Biopharma wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟蹤華爾街頂級評級和表現最佳的研究分析師及其每天推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 Theravance Biopharma 並不在名單上。</p>
</div><p>While Theravance Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Theravance Biopharma 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Theravance 生物製藥公司（NASDAQ:TBPH）被分析師給予平均評級為 “適度買入”